How Synthetic Cannabinoids Differ From Natural Cannabis: Stronger Effects, Greater Risks
Synthetic cannabinoids produce more intense desired and adverse effects than cannabis because they are full receptor agonists with higher binding affinity, with neurological and cardiovascular complications that can be severe.
Quick Facts
What This Study Found
This review provided a state-of-the-art overview of both natural and synthetic cannabinoids, explaining why synthetic versions produce more extreme effects.
The key pharmacological difference: THC is a partial agonist at CB1 receptors (it activates them partially), while most synthetic cannabinoids are full agonists (they activate receptors to their maximum). Combined with higher receptor binding affinity, this explains why synthetic cannabinoid effects are more intense across the board, both desired effects and side effects.
Neurological and cardiovascular complications are the most commonly reported adverse effects after synthetic cannabinoid poisoning. While most cases respond to conventional supportive care, severe outcomes including death occur in a minority of cases, predominantly with synthetic cannabinoids rather than natural cannabis.
The review also highlighted the endocannabinoid system's involvement in multiple neurotransmission pathways, explaining the broad range of both therapeutic and adverse effects of cannabinoid compounds.
Key Numbers
The review notes neurological and cardiovascular effects as the primary adverse outcomes, with severe cases mainly occurring with synthetic rather than natural cannabinoids.
How They Did This
Review article synthesizing current knowledge on the pharmacology, effects, and risks of natural and synthetic cannabinoids, with emphasis on the receptor-level differences that explain their distinct clinical profiles.
Why This Research Matters
Understanding the pharmacological basis for why synthetic cannabinoids are more dangerous than cannabis is essential for clinicians treating poisoning cases and for public health messaging targeting users who may assume synthetic products are similar to natural cannabis.
The Bigger Picture
The partial versus full agonist distinction is crucial. THC has a built-in safety ceiling because it can only partially activate CB1 receptors. Synthetic cannabinoids lack this ceiling, which means there is no pharmacological limit on how strongly they stimulate the receptor system, explaining the overdose risk that does not exist with natural cannabis.
What This Study Doesn't Tell Us
Narrative review without systematic search methodology. The rapidly evolving landscape of synthetic cannabinoids means any review is quickly outdated. Case severity data is largely drawn from case reports and poison center data rather than controlled studies.
Questions This Raises
- ?Are there structural features of synthetic cannabinoids that predict severity of adverse effects?
- ?Would legal cannabis access reduce synthetic cannabinoid use and associated harms?
- ?Could partial agonist synthetic cannabinoids be designed for therapeutic use?
Trust & Context
- Key Stat:
- Synthetic cannabinoids are full receptor agonists; THC is only a partial agonist
- Evidence Grade:
- Review synthesizing pharmacological and clinical evidence. Moderate because it draws on established receptor pharmacology and clinical case data.
- Study Age:
- Published in 2017.
- Original Title:
- Focus on cannabinoids and synthetic cannabinoids.
- Published In:
- Clinical pharmacology and therapeutics, 101(2), 220-229 (2017)
- Authors:
- Le Boisselier, R, Alexandre, J, Lelong-Boulouard, V, Debruyne, D
- Database ID:
- RTHC-01431
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why are synthetic cannabinoids stronger than marijuana?
THC partially activates CB1 receptors (partial agonist), creating a natural ceiling on how strong the effect can be. Synthetic cannabinoids fully activate these receptors (full agonists) with no ceiling, and often bind with higher affinity, producing more intense effects.
What are the main dangers of synthetic cannabinoids?
Neurological complications (seizures, psychosis, altered consciousness) and cardiovascular effects are the most commonly reported serious adverse events. While most cases respond to supportive care, severe outcomes including death are possible.
Read More on RethinkTHC
- THC-purity-potency-label-meaning
- dab-concentrate-addiction-withdrawal
- delta-8-addiction-withdrawal
- edible-addiction-withdrawal-different
- edibles-psychosis-emergency-room
- healthiest-way-to-consume-cannabis
- how-cannabis-products-made-concentrates-edibles
- laced-weed-fentanyl-contaminated-vape
- legal-weed-vs-street-weed-quality-safety
- quitting-dabs-withdrawal
- quitting-edibles-withdrawal
- sativa-vs-indica-difference-myth
- weed-potency-withdrawal
Cite This Study
https://rethinkthc.com/research/RTHC-01431APA
Le Boisselier, R; Alexandre, J; Lelong-Boulouard, V; Debruyne, D. (2017). Focus on cannabinoids and synthetic cannabinoids.. Clinical pharmacology and therapeutics, 101(2), 220-229. https://doi.org/10.1002/cpt.563
MLA
Le Boisselier, R, et al. "Focus on cannabinoids and synthetic cannabinoids.." Clinical pharmacology and therapeutics, 2017. https://doi.org/10.1002/cpt.563
RethinkTHC
RethinkTHC Research Database. "Focus on cannabinoids and synthetic cannabinoids." RTHC-01431. Retrieved from https://rethinkthc.com/research/le-2017-focus-on-cannabinoids-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.